dapagliflozin: Clinical Trials

614 trials of dapagliflozin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

320 completed, 105 unknown, 78 recruiting, 37 active not recruiting. 190 Phase 4, 160 Phase 3, 126 Phase 2, 80 Phase 1, 48 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 4190Completed 100, Unknown 39, Recruiting 22, Terminated 9, Active not recruiting 8, Not yet recruiting 6, Withdrawn 3, Enrolling by invitation 2, Suspended 1
Phase 3160Completed 90, Recruiting 24, Unknown 21, Active not recruiting 12, Not yet recruiting 6, Terminated 3, Withdrawn 3, Suspended 1
Phase 2126Completed 51, Recruiting 19, Not yet recruiting 16, Unknown 16, Active not recruiting 11, Terminated 6, Withdrawn 6, Enrolling by invitation 1
Phase 180Completed 58, Unknown 6, Recruiting 5, Terminated 5, Active not recruiting 3, Not yet recruiting 3
Not applicable48Completed 22, Unknown 12, Recruiting 6, Active not recruiting 4, Not yet recruiting 4
Early Phase 16Unknown 3, Active not recruiting 1, Completed 1, Recruiting 1

Follow dapagliflozin: new trials by email Literature Review of dapagliflozin trials Research Report on dapagliflozin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dapagliflozin in Patients With Non-Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Dapagliflozin 10mg, Dapagliflozin Placebo - Nonobstructive Hypertrophic Cardiomyopathy
Phase 4Not yet recruitingYonsei University4402027-01-022026-10-27
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin - Type 1 Diabetes Mellitus With Diabetic Nephropathy
Phase 2Not yet recruitingUniversity Medical Center Groningen362027-01-012026-10-20
Validation & Intervention Testing for Aging, Longevity and Healthspan
Dapagliflozin 10Mg Oral Tablet, Semaglutide oral, Placebo - Aging, Functional Decline
Phase 2Not yet recruitingThe University of Texas Health Science Center at San Antonio12002027-01-012026-11-06
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment - No Reflow Phenomenon, Reperfusion Injuries, Myocardial
Phase 2Not yet recruitingAl-Azhar University1002027-01-012026-10-27
Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis
Dapagliflozin, Empagliflozin, Methotrexate - Rheumatoid Arthritis (RA)
Phase 2Not yet recruitingAl-Azhar University902026-12-012026-10-08
Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis
Dapagliflozin (DAPA), Spironolactone (drug), Spironolactone + Dapagliflozin - Aortic Stenosis
Phase 2Not yet recruitingUniversity College, London4452026-12-012026-09-11
Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes
Acetazolamide 62.5 mg, Acetazolamide 125 mg, Acetazolamide 250 mg - T2D
Phase 2Not yet recruitingUniversity Health Network, Toronto202026-12-012026-10-29
Dapagliflozin for Long COVID Syndrome
Dapagliflozin (DAPA), Placebo - COVID - 19, Long COVID Syndrome
Phase 3Not yet recruitingOttawa Heart Institute Research Corporation1922026-12-012026-10-30
iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)
N0892, Januvia® + Glifage XR® + Placebo, Forxiga® + Glifage XR® + Placebo - Diabetes Mellitus, Type 2
Phase 3WithdrawnEurofarma Laboratorios S.A.2026-11-302025-12-18
Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy
Forxiga - Glomerulonephritis
Phase 2Not yet recruitingCentre Hospitalier Universitaire de Nice202026-11-012026-06-22
Efficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
Placebo, Dapagliflozin (10mg Tab) - Rheumatoid Arthritis (RA
Phase 1 / Phase 2Not yet recruitingTanta University1002026-10-302026-10-28
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
Rezdiffra, Resmetirom, ACTOS/pioglitazone - MASH - Metabolic Dysfunction-Associated Steatohepatitis
Phase 4RecruitingMadrigal Pharmaceuticals, Inc.1502026-10-072026-11-16
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab) - MAFLD in Prediabetes and Diabetes
Phase 4Not yet recruitingSherihan AboElyazed Mohamed Khalil662026-10-012026-10-23
Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD
Metformin + Dapagliflozin, Metformin - Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
Not applicableNot yet recruitingThe 95th Hospital of Putian,Putian, Fujian, China842026-10-012026-08-21
Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome
Metformin, Dapagliflozin (10mg Tab) - Poly Cystic Ovary Syndrome
Phase 2 / Phase 3Not yet recruitingTanta University602026-09-102026-09-09
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin - Renal Insufficiency, Chronic
Phase 3RecruitingAstraZeneca28002026-09-012026-09-24
Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes
Dapagliflozin (10mg Tab) - Myelodysplastic Syndromes (MDS), Anemia
Phase 2Not yet recruitingSeug yun Yoon, MD372026-09-012026-04-08
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
Dapagliflozin, Metformin, Common Lifestyle Program - Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
Phase 4Not yet recruitingSultan Qaboos University1102026-09-012026-06-10
SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial
SGLT2i, Placebo - Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors
Phase 2Not yet recruitingOdense University Hospital1842026-09-012026-07-02
aDAPt-ANOCA: Dapagliflozin for the Treatment of Angina With Non-Obstructive Coronary Artery Disease (ANOCA)
Dapagliflozin (10mg Tab), Placebo ( FE) - Angina With Non-Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction (CMD)
Phase 2Not yet recruitingThe Christ Hospital1202026-09-012026-08-03

Showing 20 of 614. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (226)  ·  Diabetes Mellitus (60)  ·  Heart Failure (58)  ·  Renal Insufficiency, Chronic (45)  ·  Diabetes Mellitus, Type 1 (25)  ·  Hypertension (14)  ·  Obesity (12)  ·  Prediabetic State (12)  ·  Breast Neoplasms (11)  ·  Insulin Resistance (11)  ·  Myocardial Infarction (11)  ·  Atrial Fibrillation (10)  ·  Coronary Artery Disease (10)  ·  Diabetic Nephropathies (10)  ·  Hyperglycemia (10)

Sponsors

AstraZeneca (125)  ·  The University of Texas Health Science Center at San Antonio (13)  ·  Mansoura University (10)  ·  Assiut University (9)  ·  LG Chem (8)  ·  Ain Shams University (7)  ·  Tanta University (7)  ·  University of Guadalajara (6)  ·  Washington University School of Medicine (6)  ·  Beni-Suef University (5)  ·  Boryung Pharmaceutical Co., Ltd (5)  ·  Brigham and Women's Hospital (5)  ·  Dong-A ST Co., Ltd. (5)  ·  Medical University of Vienna (5)  ·  The University of Hong Kong (5)

Countries

United States (170)  ·  South Korea (68)  ·  China (62)  ·  Egypt (58)  ·  Mexico (56)  ·  Canada (55)  ·  Germany (50)  ·  United Kingdom (45)  ·  Spain (41)  ·  Poland (40)  ·  Brazil (35)  ·  Italy (35)  ·  Sweden (32)  ·  India (31)  ·  Japan (31)

Top investigators

Mikhail Kosiborod, MD (4)  ·  Eugenio Cersosimo, MD,PhD (3)  ·  Ralph A DeFronzo, MD (3)  ·  Ralph DeFronzo, MD (3)  ·  Anna Maria Langkilde (2)  ·  Anna Maria Langkilde, MD (2)  ·  Bassem Zarif, MD (2)  ·  Hiddo J Lambers Heerspink, PhD, PharmD (2)  ·  Jan Eriksson, MD (2)  ·  Moheb Magdy Mouris, MD (2)

Results publications

PMID 38770818, PMID 26894924, PMID 31535829, PMID 26378978, PMID 32970396, PMID 27461213, PMID 28605608, PMID 31081589, PMID 33368935, PMID 30415602, PMID 32865377, PMID 35403243, PMID 36027570, PMID 40913594, PMID 19114612, PMID 23668478, PMID 25352655, PMID 25425451, PMID 27440829, PMID 29802530, PMID 30756462, PMID 30990260, PMID 31196815, PMID 31364269, PMID 31843945, PMID 32559474, PMID 32691513, PMID 32877652, PMID 32946821, PMID 34447992, PMID 34473343, PMID 34693515, PMID 35241246, PMID 36189985, PMID 36811901, PMID 36881399, PMID 37170711, PMID 37203441, PMID 37210608, PMID 37211977, PMID 37220172, PMID 37227937, PMID 37886880, PMID 38017482, PMID 38059368, PMID 38299639, PMID 38320525, PMID 38334499, PMID 38430085, PMID 39046727

NIH funding

2023 (13), 2014 (9), 2015 (8), 2016 (6), 2017 (5), 2018 (4), 2025 (4), 2019 (3), R01DK024092 (3), R01DK107680 (3), 1OT2HL156812-01 (1), K23DK142042 (1), K23HL150236 (1), KL2TR003016 (1), P30AG044271 (1)